Clinical Trial Update: Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia [Phase 2]

View source ↗

Summary

Phase 2 study of GSK1278863 in rhEPO-hyporesponsive anemia in hemodialysis-dependent chronic kidney disease was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• GSK1278863

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anemia | Phase 2 | Status: TERMINATED | Results posted: 2017-06-21